The Latest Cardiac and Vascular News
alfapump achieves pre-specified primary effectiveness endpoints with statistical significance at six months post-implantation: o 100% median per-patient reduction in therapeutic paracentesis (TP) post- vs preimplantation (p<0.001) o 77% of patients with at least 50% reduction in number of TP post- vs pre-implantation (p<0.001) alfapump primary safety endpoint data in line […]
GENEVA, Oct. 25, 2022 /PRNewswire/ — Following our communication last week “MedAlliance to be acquired by Cordis”, MedAlliance is pleased to make the following announcement: SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received FDA Investigational Device Exemption (IDE) approval to initiate its coronary pivotal clinical trial. This is the first sustained limus release coronary […]
ARISE-HF is a global registrational study in 675 patients with Diabetic Cardiomyopathy (DbCM), evaluating the potential of AT-001 to improve or prevent worsening of cardiac function vs. placebo Primary study endpoint is cardiac functional capacity (measured by Peak VO2) at 15 months DbCM is a form of heart failure affecting […]
Anticipated New Patent Will Add to the Istaroxime Patent Estate and Provide Intellectual Property Protection Until Late 2039 WARRINGTON, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that the United States Patent […]
WASHINGTON–(BUSINESS WIRE)–CorVista Health, Inc, a digital health company dedicated to improving cardiovascular disease diagnosis, announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CorVista System as a first non-invasive point of care diagnostic solution for patients with suspected pulmonary hypertension. The FDA’s Breakthrough […]
DEKRA has provided notified body approval of all changes implemented by CARMAT PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of Aeson®, the world’s most advanced total artificial heart, designed to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, announced today that it has […]
The RELIEVE-HF trial of the Ventura® Shunt System includes patients with reduced and preserved left ventricular function etiologies for heart failure CAESAREA, Israel, Oct. 24, 2022 /PRNewswire/ — V-Wave, announced today the completion of enrollment in RELIEVE-HF, a prospective, randomized, double-blinded, sham-controlled, multi-center pivotal clinical trial. The RELIEVE-HF study is assessing the safety […]
Technology will bundle and accelerate prior authorization for cardiovascular and surgical services BOSTON, Oct. 24, 2022 /PRNewswire/ — Today Cohere Health, a leader in intelligent utilization management (UM) technology, announced that Humana Inc. (NYSE: HUM) will expand its use of Cohere’s digital UM collaboration platform to enable seamless prior authorization for cardiovascular and surgical services. […]
New Jersey’s only hospital to achieve a 3-star rating for transcatheter aortic valve replacement ENGLEWOOD, N.J., Oct. 24, 2022 /PRNewswire/ — Englewood Health has been recognized by The Society of Thoracic Surgeons with a 3-star rating—the highest possible quality rating—for transcatheter aortic valve replacement (TAVR). This mark of distinction reflects the accomplishments of the […]
Medical Center of Excellence to leverage the Company’s PURE EP™ System to further its research and educational objectives as a leader in cardiac electrophysiology Clinical investigations conducted by Cleveland Clinic could expand clinical parameters of BioSig’s digital signal processing technology for arrhythmia care BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or […]
